US Patent

US8883783 — Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-Nâ²-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Composition of Matter · Assigned to Ambit Bioscience Corp · Expires 2027-03-16 · 1y remaining

Vulnerability score 30/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects solid forms of the drug substance quizartinib dihydrochloride and methods for making and using them.

USPTO Abstract

Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-Nâ²-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: US8883783
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-03-16
Drug substance claim: Yes
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.